Liver News and Research

RSS

Scientists confirm metabolic syndrome may raise risk of liver cancer

Scientists have confirmed that metabolic syndrome, a constellation of conditions that increases the risk of heart disease and diabetes, may also increase the risk of the two most common types of liver cancer, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

4 Apr 2011

Study: Diabetes is linked with risk of cancer and mortality

Results of the NIH-AARP Diet and Health Study revealed that diabetes is associated with lower risk of prostate cancer in men but with higher risk of other cancers in both men and women.

4 Apr 2011

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.

2 Apr 2011

Experts must monitor new antiviral compounds for HCV treatment

Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus must be prescribed and monitored by experts and specialists to ensure resistance is minimised.

2 Apr 2011

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve patients chronically infected with hepatitis C virus genotype 1.

2 Apr 2011

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD reported that final results from a Phase III study of 'Victrelis', its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a marketed by Roche Products Limited, and ribavirin therapy were presented for the first time today as part of a late-breaker poster session at The International Liver Congress / 46th European Association for the Study of the Liver annual meeting.

2 Apr 2011

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.

2 Apr 2011

Thalidomide provides new hope for patients with difficult to treat liver cancer

Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma, according to data presented at the International Liver Congress 2011.

2 Apr 2011

Prevalence of NAFLD in US expected to increase by 50% in 2030: Study

According to new data presented today at the International Liver CongressTM, the United States could soon be faced with an epidemic of Non-Alcoholic Fatty Liver Disease, one of the major contributing factors of chronic liver disease, considered as one of the major causes of morbidity and mortality worldwide.

2 Apr 2011

Series of new clinical trials confirm range of viable treatment options for HCV patients

Highly anticipated data from a number of clinical trials presented for the first time at the International Liver CongressTM confirmed that a range of new proteases inhibitors will help treat patients who have previously failed therapy for the treatment of chronic hepatitis C.

2 Apr 2011

Blocking TNF-related apoptosis-inducing ligand pathway partially reconstitutes HBV-specific T cells

A new study presented today at the International Liver Congress shows a novel pathway where activated natural killer (NK) cells expressing death ligands may excessively down-modulate the antiviral immune response in chronic HBV patients.

2 Apr 2011

Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress

Early data from phase I trials of an HCV vaccine presented today at the International Liver CongressTM show encouraging results, with high immunogenicity and good safety profile.

2 Apr 2011

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype of HCV to treat.

1 Apr 2011

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

1 Apr 2011

Donation after cardiac death may broaden the scope of organ donor selection

Findings from two new studies presented today at the International Liver CongressTM confirm that there are options for clinicians to expand the pool of liver grafts for use in patients with liver disease.

1 Apr 2011

NIH combats obesity epidemic with new strategic research plan

To combat the obesity epidemic, the National Institutes of Health is encouraging diverse scientific investigations through a new Strategic Plan for NIH Obesity Research.

1 Apr 2011

OPO staff working with ICU team can help recover more organs from brain dead donors

More than twice as many lungs and nearly 50 percent more kidneys could be recovered for transplant operations if intensive care physicians were to work with organ procurement organization (OPO) coordinators to monitor and manage donor bodies after brain death has occurred, according to an analysis by UPMC and University of Pittsburgh School of Medicine physicians that is now in the online version of the American Journal of Transplantation.

1 Apr 2011

New findings from two modeling studies can help reduce HCV-related deaths in Europe

New findings from two modeling studies presented at the International Liver Congress support the call to action from medical experts and patients in relation to the challenge health inequalities represent in the diagnosis and access to HCV treatment.

1 Apr 2011

Study finds AKIN criteria effective in cirrhosis detection

The first clinical study investigating the use of the AKIN criteria in cirrhosis has shown significant benefits that have the potential to change future diagnosis, according to results from a Spanish study presented today at the International Liver Congress.

1 Apr 2011

Lymphocyte-hepatocyte interactions: Hepatitis C virus changes the rules

New data presented at the International Liver CongressTM today show the existence of novel interactions between T cells and hepatocytes that are regulated by HCV infection, providing a novel understanding of how HCV persists in the liver.

1 Apr 2011

Liver News and Research

Scientists confirm metabolic syndrome may raise risk of liver cancer

Study: Diabetes is linked with risk of cancer and mortality

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Experts must monitor new antiviral compounds for HCV treatment

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Thalidomide provides new hope for patients with difficult to treat liver cancer

Prevalence of NAFLD in US expected to increase by 50% in 2030: Study

Series of new clinical trials confirm range of viable treatment options for HCV patients

Blocking TNF-related apoptosis-inducing ligand pathway partially reconstitutes HBV-specific T cells

Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

Donation after cardiac death may broaden the scope of organ donor selection

NIH combats obesity epidemic with new strategic research plan

OPO staff working with ICU team can help recover more organs from brain dead donors

New findings from two modeling studies can help reduce HCV-related deaths in Europe

Study finds AKIN criteria effective in cirrhosis detection

Lymphocyte-hepatocyte interactions: Hepatitis C virus changes the rules

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News